乳腺癌是女性最常见的恶性肿瘤,全世界每年约有120万新发乳腺癌患者,约有50万患者死亡。在我国,每年新诊断为乳腺癌的患者已增至近17万人,死亡人数近4万~([1]),不仅严重威胁着女性的健康和生活质量,而且给全球卫生系统带来沉重的负担。复发和转移是导致乳腺癌患者死亡的主要原因,对于转移性乳腺癌的治疗一直是乳腺癌治疗的前沿课题~([2])。雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2 Breast cancer is the most common malignancy in women, with about 1.2 million new breast cancers worldwide each year and about 500,000 deaths. In China, the number of newly diagnosed breast cancer patients has increased to nearly 170,000 and the death toll nearly 40,000 annually ([1]), which not only seriously threatens women’s health and quality of life, but also brings heavy burden to the global health system burden. Recurrence and metastasis are the major causes of death in patients with breast cancer, and the treatment of metastatic breast cancer has been a frontier issue in breast cancer treatment (2). Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2